Despite recommendations from the American College of Rheumatology (ACR) and other international societies, the use of treat‐to‐target strategies with urate‐lowering therapy (ULT) has not increased over the past 20 years. To encourage more adherence to ULT for treating patients with gout, the ACR updated its guidelines to provide stronger evidence in favor of ULT as the preferred therapeutic agent. Which of the following agents does the ACR recommend for first-line therapy for patients with gout?